This website uses cookies to understand how you use the website and to improve your experience. By continuing to use the website, you accept the University of New England’s use of cookies and similar technologies. To learn more about our use of cookies and how to manage your browser cookie settings, please review our Privacy Notice.

Accept

UNE receives new funding to study Alzheimer’s disease

Benjamin Harrison, assistant professor of Biomedical Sciences
Benjamin Harrison, assistant professor of Biomedical Sciences

September 23, 2019

Benjamin Harrison, Ph.D., assistant professor in the Biomedical Science Department in the College of Osteopathic Medicine, recently received a grant of more than $315,000 from the National Institute of General Medical Sciences of the National Institutes of Health (NIH) to study Alzheimer’s disease.

There are currently no available therapeutics that can prevent the symptoms of Alzheimer’s disease. It has been more than 15 years since a new medication to treat it has been approved by the U.S. Food and Drug Administration (FDA).

The goal of Harrison’s project is to help develop effective therapies that target multiple facets of Alzheimer’s disease.

Harrison will work to create a better understanding of specific biochemical pathways involved in the formation of brain lesions, a major component of the disease, by looking at how these specific pathways can be modified to promote cell survival and maintain the health of cells that are typically damaged by Alzheimer’s disease.

The hope is to discover therapies that will prevent, delay or even reverse brain lesions. Moving forward Alzheimer’s disease treatments will most likely be a combination of therapies that will be adjusted as the disease progresses and modified for different patients.

Harrison’s grant will supplement the Center of Biomedical Research Excellence (COBRE) for the Study of Pain and Sensory Function, an existing NIH funded program at UNE.

Read about it in the Journal Tribune

 

Groups audience: